Prioritizing kids first is core to our mission, and our pipeline reflects that.

We believe our portfolio of technology has the potential to make a significant impact in how pediatric brain tumors are treated, as well as expand to other types of CNS tumors in adults, including glioblastoma and brain metastases.

BCB-276

BCB-276 is BrainChild Bio’s lead single-target CAR T cell therapy targeting B7-H3, a target universally expressed in DIPG, and is designed to address the urgent unmet need for children and young adults with this devastating disease. Building on encouraging Phase 1 clinical experience, BCB-276 is advancing Illuminate, a pivotal registrational trial designed in alignment with the U.S. Food and Drug Administration (FDA) to support a future Biologics License Application (BLA) and a potential path to the first FDA-approved immunotherapy for DIPG.

Information about Illuminate can be found at https://clinicaltrials.gov/study/NCT07680439.

BCB-214

BCB-214 is BrainChild Bio’s next-generation, triple-targeting CAR T cell therapy (EGFR x B7-H3 x IL13Ralpha2), designed to address the complex biology of glioblastoma (GBM), one of the most aggressive and lethal adult brain tumors, as well as pediatric brain tumors such as diffuse midline glioma (DMG). By combining a triple-targeting strategy with BrainChild Bio’s functional retention technologies and repetitive intracerebroventricular dosing approach, BCB-214 is designed to overcome tumor heterogeneity and the immunosuppressive tumor microenvironment that have historically limited the effectiveness of CAR T therapies in GBM.

Expanded Access Policy

BrainChild Bio is committed to developing advanced cellular therapies for people of all ages with tumors of the central nervous system.

Our goal is to develop new treatment options responsibly and thoughtfully. We believe that clinical trials are the most appropriate way to understand the safety and effectiveness of our therapies and work toward making them broadly available to those who may benefit from them.

Expanded access, sometimes referred to as compassionate use, is a regulatory pathway that allows people to seek access to investigational products outside of a clinical trial.

At this time, access to our investigational products is available only through participation in clinical trials.  BrainChild Bio does not provide any investigational products through expanded access or compassionate use programs.

Information about our clinical trial can be found at https://clinicaltrials.gov/study/NCT07680439.